Spectrum SPI-POZ-202 (Non-Small Cell Lung Cancer) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if a study drug poziotinib is safe and effective in treating NSCLC with EGFR or HER2 Exon 20 Insertion Mutation.
Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 Exon 20 Insertion Mutation
Who Can Participate in the Study?
Adults who have confirmed non-small cell lung cancer with EGFR or HER2 Exon 20 Insertion Mutation.
What is Involved?
Based upon your Exon 20 insertion mutation-positive status (EGFR or HER2), you will be assigned to one of 4 groups and you will:
- Take poziotinib pills (10 or 16 mg) by mouth daily with breakfast at the same time each morning.
- Have blood samples and possibly a small piece of tissue removed from your lung to see what type of lung cancer cells you have
- Have other tests, exams, and procedures for study purposes and your standard of care.
- Be in the study for up to 24 months after the start of study drug or until your condition worsens or you have intolerable side effects.
Study Details
